[go: up one dir, main page]

RU2010133049A - MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS - Google Patents

MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS Download PDF

Info

Publication number
RU2010133049A
RU2010133049A RU2010133049/15A RU2010133049A RU2010133049A RU 2010133049 A RU2010133049 A RU 2010133049A RU 2010133049/15 A RU2010133049/15 A RU 2010133049/15A RU 2010133049 A RU2010133049 A RU 2010133049A RU 2010133049 A RU2010133049 A RU 2010133049A
Authority
RU
Russia
Prior art keywords
aqueous
antibodies
hiv
solution
activated potentiated
Prior art date
Application number
RU2010133049/15A
Other languages
Russian (ru)
Inventor
Олег Ильич Эпштейн (RU)
Олег Ильич Эпштейн
Сергей Александрович Тарасов (RU)
Сергей Александрович Тарасов
Original Assignee
Олег Ильич Эпштейн (RU)
Олег Ильич Эпштейн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олег Ильич Эпштейн (RU), Олег Ильич Эпштейн filed Critical Олег Ильич Эпштейн (RU)
Priority to RU2010133049/15A priority Critical patent/RU2010133049A/en
Priority to FR1156471A priority patent/FR2963562A1/en
Priority to PCT/IB2011/002469 priority patent/WO2012017327A2/en
Priority to EA201300134A priority patent/EA032021B1/en
Priority to UAA201300102A priority patent/UA113389C2/en
Priority to US13/135,894 priority patent/US20120263725A1/en
Publication of RU2010133049A publication Critical patent/RU2010133049A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Лекарственное средство для профилактики инфицирования ВИЧ, профилактики и лечения заболеваний, вызываемых ВИЧ или ассоциированных с ВИЧ, в том числе СПИДа, характеризующееся тем, что содержит активированную потенцированную форму антител к CD4 рецептору. ! 2. Лекарственное средство по п.1, характеризующееся тем, что активированную потенцированную форму антител к CD4 рецептору используют в виде активированного потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом последовательного многократного разведения матричного исходного раствора антител в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения. ! 3. Лекарственное средство по п.1 или 2, характеризующееся тем, что выполнено в твердой лекарственной форме и содержит технологически необходимое количество нейтрального носителя, насыщенного водным или водно-спиртовым раствором активированной потенцированной формы антител к CD4 рецептору, и фармацевтически приемлемые добавки. ! 4. Лекарственное средство по п.1 или 2, характеризующееся тем, что водный или водно-спиртовой раствор активированной потенцированной формы антител к CD4 рецептору получен путем многократного последовательного разведения матричного - исходного - раствора антител в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения, при этом концентрация матричного раствора составляет 0,5÷5,0 мг/мл. ! 5. Лекарственное средство по п.1 или 2, характеризующееся тем, что водный или водно-спиртовой раствор активированной потенцированной фор� 1. A drug for the prevention of HIV infection, the prevention and treatment of diseases caused by HIV or associated with HIV, including AIDS, characterized in that it contains an activated potentiated form of antibodies to the CD4 receptor. ! 2. The drug according to claim 1, characterized in that the activated potentiated form of antibodies to the CD4 receptor is used in the form of an activated potentiated aqueous or aqueous-alcoholic solution, the activity of which is due to the process of sequential multiple dilution of the matrix initial solution of antibodies in an aqueous or aqueous-alcoholic solvent in combination with external mechanical action - vertical shaking of each dilution. ! 3. The drug according to claim 1 or 2, characterized in that it is in solid dosage form and contains the technologically necessary amount of a neutral carrier saturated with an aqueous or aqueous-alcoholic solution of an activated potentiated form of antibodies to the CD4 receptor, and pharmaceutically acceptable additives. ! 4. The drug according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solution of the activated potentiated form of antibodies to the CD4 receptor is obtained by repeated serial dilution of the matrix - initial - antibody solution in combination with an external mechanical action - vertical shaking of each dilution while the concentration of the matrix solution is 0.5 ÷ 5.0 mg / ml ! 5. The drug according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solution of the activated potentiated form

Claims (10)

1. Лекарственное средство для профилактики инфицирования ВИЧ, профилактики и лечения заболеваний, вызываемых ВИЧ или ассоциированных с ВИЧ, в том числе СПИДа, характеризующееся тем, что содержит активированную потенцированную форму антител к CD4 рецептору.1. A drug for the prevention of HIV infection, the prevention and treatment of diseases caused by HIV or associated with HIV, including AIDS, characterized in that it contains an activated potentiated form of antibodies to the CD4 receptor. 2. Лекарственное средство по п.1, характеризующееся тем, что активированную потенцированную форму антител к CD4 рецептору используют в виде активированного потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом последовательного многократного разведения матричного исходного раствора антител в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения.2. The drug according to claim 1, characterized in that the activated potentiated form of antibodies to the CD4 receptor is used in the form of an activated potentiated aqueous or hydroalcoholic solution, the activity of which is due to the process of sequential multiple dilution of the matrix initial antibody solution in an aqueous or hydroalcoholic solvent in combination with external mechanical action - vertical shaking of each dilution. 3. Лекарственное средство по п.1 или 2, характеризующееся тем, что выполнено в твердой лекарственной форме и содержит технологически необходимое количество нейтрального носителя, насыщенного водным или водно-спиртовым раствором активированной потенцированной формы антител к CD4 рецептору, и фармацевтически приемлемые добавки.3. The drug according to claim 1 or 2, characterized in that it is made in solid dosage form and contains the technologically necessary amount of a neutral carrier saturated with an aqueous or aqueous-alcoholic solution of an activated potentiated form of antibodies to the CD4 receptor, and pharmaceutically acceptable additives. 4. Лекарственное средство по п.1 или 2, характеризующееся тем, что водный или водно-спиртовой раствор активированной потенцированной формы антител к CD4 рецептору получен путем многократного последовательного разведения матричного - исходного - раствора антител в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения, при этом концентрация матричного раствора составляет 0,5÷5,0 мг/мл.4. The drug according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solution of the activated potentiated form of antibodies to the CD4 receptor is obtained by multiple sequential dilutions of the matrix - initial - antibody solution in combination with an external mechanical action - vertical shaking of each dilution while the concentration of the matrix solution is 0.5 ÷ 5.0 mg / ml 5. Лекарственное средство по п.1 или 2, характеризующееся тем, что водный или водно-спиртовой раствор активированной потенцированной формы антител к CD4 рецептору используют в виде смеси различных, преимущественно сотенных разведений, приготовленных по гомеопатической технологии.5. The drug according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solution of the activated potentiated form of antibodies to the CD4 receptor is used in the form of a mixture of various, mainly hundred, dilutions prepared by homeopathic technology. 6. Лекарственное средство по п.3, характеризующееся тем, что фармацевтически приемлемые добавки включают лактозу, целлюлозу микрокристаллическую и магния стеарат.6. The drug according to claim 3, characterized in that the pharmaceutically acceptable additives include lactose, microcrystalline cellulose and magnesium stearate. 7. Способ профилактики инфицирования ВИЧ, профилактики и лечения заболеваний, вызываемых ВИЧ или ассоциированных с ВИЧ, в том числе СПИДа, характеризующийся тем, что в организм вводят активированную потенцированную форму антител к CD4.7. A method for the prevention of HIV infection, the prevention and treatment of diseases caused by HIV or associated with HIV, including AIDS, characterized in that an activated potentiated form of anti-CD4 antibodies is introduced into the body. 8. Способ по п.7, характеризующийся тем, что активированную потенцированную форму антител к CD4 используют в виде активированного потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом многократного разведения матричного исходного раствора антител в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения.8. The method according to claim 7, characterized in that the activated potentiated form of antibodies to CD4 is used in the form of an activated potentiated aqueous or aqueous-alcoholic solution, the activity of which is due to the process of multiple dilution of the matrix initial solution of antibodies in an aqueous or aqueous-alcoholic solvent in combination with external mechanical action - vertical shaking of each dilution. 9. Способ по п.8, характеризующийся тем, что водный или водно-спиртовой раствор активированной потенцированной формы антител к CD4 получен путем многократного последовательного разведения матричного исходного раствора антител в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения, при этом концентрация матричного раствора составляет 0,5÷5,0 мг/мл.9. The method according to claim 8, characterized in that the aqueous or aqueous-alcoholic solution of the activated potentiated form of the anti-CD4 antibody is obtained by repeatedly diluting the matrix antibody stock solution in combination with an external mechanical action — vertical shaking of each dilution, wherein the concentration of the matrix solution is 0.5 ÷ 5.0 mg / ml. 10. Способ лечения по п.7 или 8, характеризующийся тем, что используют приготовленные в виде единого лекарственного препарата - одной лекарственной формы смесь различных разведении антител к CD4, приготовленных по гомеопатической технологии. 10. The method of treatment according to claim 7 or 8, characterized in that use is made of a mixture of various dilutions of antibodies to CD4 prepared according to homeopathic technology prepared as a single drug.
RU2010133049/15A 2010-08-06 2010-08-06 MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS RU2010133049A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
RU2010133049/15A RU2010133049A (en) 2010-08-06 2010-08-06 MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
FR1156471A FR2963562A1 (en) 2010-08-06 2011-07-15 PHARMACEUTICAL COMPOSITION AND USE THEREOF IN A PROCESS FOR INHIBITING PRODUCTION OF OR AMPLIFYING THE ELIMINATION OF P24 PROTEIN
PCT/IB2011/002469 WO2012017327A2 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
EA201300134A EA032021B1 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and method of treating and preventing the diseases caused by hiv and/or associated with hiv
UAA201300102A UA113389C2 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
US13/135,894 US20120263725A1 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133049/15A RU2010133049A (en) 2010-08-06 2010-08-06 MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS

Publications (1)

Publication Number Publication Date
RU2010133049A true RU2010133049A (en) 2012-02-20

Family

ID=44906251

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010133049/15A RU2010133049A (en) 2010-08-06 2010-08-06 MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS

Country Status (5)

Country Link
EA (1) EA032021B1 (en)
FR (1) FR2963562A1 (en)
RU (1) RU2010133049A (en)
UA (1) UA113389C2 (en)
WO (1) WO2012017327A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2181297C2 (en) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Method of treatment of pathological syndrome and medicinal agent
RU2192888C1 (en) 2001-02-15 2002-11-20 Эпштейн Олег Ильич Medicinal agent and method of treatment of pathological syndrome
RU2001134982A (en) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн METHOD OF IMMUNE RESPONSE CORRECTION AND MEDICINE
UA76641C2 (en) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Homeopathic medicinal agent and method for curing diseases of prostate
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
WO2004082597A2 (en) 2003-03-14 2004-09-30 Nutrition Research, Inc. Homeopathic formulations useful for treating pain and/or inflammmation

Also Published As

Publication number Publication date
WO2012017327A2 (en) 2012-02-09
WO2012017327A3 (en) 2012-04-12
EA201300134A1 (en) 2014-03-31
FR2963562A1 (en) 2012-02-10
UA113389C2 (en) 2017-01-25
EA032021B1 (en) 2019-03-29

Similar Documents

Publication Publication Date Title
RU2010133048A (en) MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2010133045A (en) MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
JP2013538195A5 (en)
RU2011127226A (en) METHOD FOR TREATING INFECTIOUS DISEASES AND AN INTEGRATED MEDICINE FOR THE TREATMENT OF INFECTIOUS DISEASES
RU2010133046A (en) METHOD AND MEANS FOR INHIBITING PRODUCTS OR STRENGTHEN ELIMINATION OF PROTEIN P24
RU2010133047A (en) INTEGRATED MEDICINE AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2010133051A (en) COMPREHENSIVE MEDICINE FOR TREATMENT OF INFLUENZA TREATMENT OF VARIOUS TYPES
RU2013154072A (en) MEDICINE FOR TREATMENT OF KINETOSIS AND METHOD OF TREATMENT OF KINETOSIS
RU2010133053A (en) INTEGRATED MEDICINE FOR TREATMENT OF VIRAL DISEASES AND METHOD OF TREATMENT OF VIRAL DISEASES
RU2013154071A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF HEAD-WAYS
RU2011127055A (en) MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL-BEHAVIORAL DEVELOPMENT DISORDERS AND METHOD OF TREATMENT OF NEUROLOGICAL-BEHAVIORAL DISORDERS OF DEVELOPMENT
RU2010130358A (en) MEDICINE FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME AND METHOD FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME
RU2010133049A (en) MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2011127059A (en) NEUROTROPIC MEDICINE AND METHOD OF TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2011127052A (en) METHOD FOR TREATING THE HEAD-VARIABLE OF VARIOUS GENESIS, KINETOSIS AND VEGETOVASCULAR DYSTONIA (OPTIONS) AND MEDICINAL PRODUCT
RU2010133052A (en) INTEGRATED MEDICINE FOR TREATMENT OF VIRAL INFECTIONS AND METHOD OF TREATMENT OF VIRAL INFECTIONS
RU2010133050A (en) INTEGRATED MEDICINE FOR TREATMENT OF BACTERIAL INFECTIONS AND METHOD OF TREATMENT OF BACTERIAL INFECTIONS
RU2011127058A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2013152871A (en) DIABETES TREATMENT METHOD AND COMBINED MEDICINE
RU2010133041A (en) INTEGRATED MEDICINE AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2010130350A (en) METHOD FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING AND MEDICINAL PRODUCT FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING
RU2010131386A (en) MEDICINAL PRODUCT FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISORDERS, AND METHOD FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISEASES
RU2010133043A (en) INTEGRATED MEDICINE AND METHOD FOR PREVENTION AND TREATMENT OF INFECTIOUS VIRAL DISEASES
RU2013135854A (en) PHARMACEUTICAL COMPOSITION
RU2010130355A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS